Dale L. Bixby
About
Dale L. Bixby is a scholar working on Hematology, Genetics and Oncology.
According to data from OpenAlex, Dale L. Bixby has authored 135 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 39 papers in Genetics and 36 papers in Oncology. Recurrent topics in Dale L. Bixby's work include Acute Myeloid Leukemia Research (70 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Acute Lymphoblastic Leukemia research (35 papers). Dale L. Bixby is often cited by papers focused on Acute Myeloid Leukemia Research (70 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Acute Lymphoblastic Leukemia research (35 papers). Dale L. Bixby collaborates with scholars based in United States, Australia and Ireland. Dale L. Bixby's co-authors include Moshe Talpaz, Jörge E. Cortes, James Riddell, Lucy A. McNamara, Kathleen L. Collins, Adewunmi Onafuwa-Nuga, Bernard L. Marini, Harry P. Erba, Anthony J. Perissinotti and Daniel J. DeAngelo and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Dale L. Bixby
127 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dale L. Bixby United States | 27 | 1.6k | 1.1k | 864 | 756 | 452 | 135 | 3.2k | ||
| Peter Westervelt United States | 39 | 3.2k 2.0× | 1.8k 1.6× | 638 0.7× | 1.4k 1.8× | 721 1.6× | 195 | 5.7k | ||
| Paul V. O’Donnell United States | 35 | 2.6k 1.6× | 541 0.5× | 472 0.5× | 1.3k 1.8× | 738 1.6× | 121 | 4.4k | ||
| Amrita Krishnan United States | 35 | 2.9k 1.8× | 2.2k 1.9× | 745 0.9× | 2.8k 3.7× | 347 0.8× | 198 | 5.6k | ||
| Janet W. Andersen United States | 26 | 1.1k 0.7× | 1.2k 1.0× | 226 0.3× | 499 0.7× | 318 0.7× | 47 | 2.6k | ||
| Brian T. Hill United States | 27 | 482 0.3× | 746 0.7× | 790 0.9× | 1.2k 1.6× | 222 0.5× | 225 | 2.7k | ||
| Ellin Berman United States | 31 | 2.2k 1.3× | 1.2k 1.1× | 992 1.1× | 1.2k 1.6× | 871 1.9× | 99 | 3.8k | ||
| Laurent Garderet France | 30 | 2.6k 1.6× | 1.7k 1.5× | 429 0.5× | 1.6k 2.1× | 205 0.5× | 125 | 3.7k | ||
| Matthias Theobald Germany | 37 | 2.4k 1.5× | 1.7k 1.5× | 534 0.6× | 2.2k 2.9× | 664 1.5× | 145 | 5.9k | ||
| Régis Costello France | 33 | 986 0.6× | 872 0.8× | 363 0.4× | 1.3k 1.8× | 134 0.3× | 153 | 3.9k | ||
| Shin Mineishi United States | 36 | 1.8k 1.1× | 1.0k 0.9× | 348 0.4× | 1.6k 2.1× | 483 1.1× | 163 | 4.2k |
Countries citing papers authored by Dale L. Bixby
Since
Specialization
Citations
This map shows the geographic impact of Dale L. Bixby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale L. Bixby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale L. Bixby more than expected).
Fields of papers citing papers by Dale L. Bixby
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dale L. Bixby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale L. Bixby. The network helps show where Dale L. Bixby may publish in the future.
Co-authorship network of co-authors of Dale L. Bixby
This figure shows the co-authorship network connecting the top 25 collaborators of Dale L. Bixby. A scholar is included among the top collaborators of Dale L. Bixby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale L. Bixby. Dale L. Bixby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Li, Li, Muharrem Müftüoğlu, Koichi Iwanaga, et al.. (2025). Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid Leukemias. Clinical Cancer Research. 31(14). 3033–3047.
2.
Burke, Patrick W., Lydia L. Benitez, Anthony J. Perissinotti, et al.. (2023). Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan. European Journal Of Haematology. 112(3). 424–432.
3.
Perissinotti, Anthony J., Bernard L. Marini, Kristen Pettit, et al.. (2023). Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring. Annals of Hematology. 102(11). 3133–3141.
4.
Daver, Naval, Anthony S. Stein, Dale L. Bixby, et al.. (2023). Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood. 142(Supplement 1). 4278–4278.
5.
Walker, Alison R., Pau Montesinos, Dale L. Bixby, et al.. (2022). Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).. Journal of Clinical Oncology. 40(16_suppl). TPS7071–TPS7071.
6.
Vincent, T., Lydia L. Benitez, Anthony J. Perissinotti, et al.. (2021). Identification of variant APL translocations PRKAR1A-RARα and ZBTB16-RARα (PLZF-RARα) through the MI-ONCOSEQ platform. Cancer Genetics. 258-259. 57–60.
7.
Patel, Twisha S, Anthony J. Perissinotti, Lindsay A Petty, et al.. (2021). Utility of methicillin‐resistant Staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML). Transplant Infectious Disease. 23(4). e13612–e13612.
8.
Perissinotti, Anthony J., Lydia L. Benitez, Daniel F. Boyer, et al.. (2021). Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. Leukemia Research. 103. 106539–106539.
9.
Chen, J., Winston Y. Lee, Jordan K. Schaefer, & Dale L. Bixby. (2020). Pure erythroid leukemia. SHILAP Revista de lepidopterología. 8(11). 2286–2288.
10.
Lancet, Jeffrey E., Geoffrey L. Uy, Laura F. Newell, et al.. (2020). Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.. Journal of Clinical Oncology. 38(15_suppl). 7510–7510.
11.
Marini, Bernard L., et al.. (2019). Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 141. 125–138.
12.
Perissinotti, Anthony J., Victoria Nachar, Dale L. Bixby, et al.. (2018). The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leukemia Research. 70. 91–96.
13.
Bixby, Dale L., Carlos E. Vigil, Joseph G. Jurcic, et al.. (2017). Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Annals of Oncology. 28. v367–v367.
14.
Uy, Geoffrey L., Jörge E. Cortes, Laura F. Newell, et al.. (2017). Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. Biology of Blood and Marrow Transplantation. 23(3). S38–S39.
15.
Marini, Bernard L., et al.. (2017). Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Annals of Hematology. 97(4). 573–584.
16.
DeAngelo, Daniel J., Brian A. Jonas, Jane L. Liesveld, et al.. (2017). GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.. Journal of Clinical Oncology. 35(15_suppl). 2520–2520.
17.
Perissinotti, Anthony J., et al.. (2017). Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy. 72(5). 1488–1495.
18.
Marini, Bernard L., et al.. (2015). Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. Journal of Oncology Pharmacy Practice. 22(6). 811–815.
19.
Talpaz, Moshe, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2015). Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).. Journal of Clinical Oncology. 33(15_suppl). 7047–7047.
20.
Malek, Sami N., Mark Kaminski, Hongxiu Li, et al.. (2013). Recurrent STAT6 Mutations In Follicular Lymphoma. Blood. 122(21). 503–503.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter Westervelt Breakdown of academic impact, for papers by Paul V. O’Donnell Breakdown of academic impact, for papers by Amrita Krishnan Breakdown of academic impact, for papers by Janet W. Andersen Breakdown of academic impact, for papers by Brian T. Hill Breakdown of academic impact, for papers by Ellin Berman Breakdown of academic impact, for papers by Laurent Garderet Breakdown of academic impact, for papers by Matthias Theobald Breakdown of academic impact, for papers by Régis Costello Breakdown of academic impact, for papers by Shin Mineishi